Across TCGA pan-cancer cohorts, GLDN mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated GLDN data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher GLDN mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated GLDN expression acts as an unfavorable survival marker.

GBM and CCRCC are the cancer types where GLDN mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Median	All	0.252	0.475	<.001	28	view →
CCRCC	DFS	Median	II,III,IV	0.471	1.000	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: GLDN tumor-vs-normal RNA expression · all GLDN data types